Vivimed Labs (NSE:VIVIMEDLAB) Total Long-Term Assets: ₹0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
42 GF Score
Price ₹5.36
GF Value ₹2.55
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs Total Long-Term Assets?

Vivimed Labs NSE:VIVIMEDLAB -0.92% 42 Total Long-Term Assets is ₹0.0 Mil as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 42/100 and a GF Value™ of ₹2.55 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Vivimed Labs's Total Long-Term Assets for the quarter that ended in Dec. 2025 was ₹0.0 Mil.

Vivimed Labs Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Total Long-Term Assets Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,606.20 7,587.50 6,560.59 6,083.27 5,932.80

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5,932.80 0.00 5,834.14 0.00
NSE:VIVIMEDLAB
42GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of ₹0.0 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Total Long-Term Assets of ₹0.0 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Vivimed Labs and its competitors.
Is Vivimed Labs' Total Long-Term Assets too high?
Vivimed Labs' current Total Long-Term Assets is ₹0.0 Mil. Overall, Vivimed Labs has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Total Long-Term Assets compare to ZTS and UTHR?
Vivimed Labs' Total Long-Term Assets of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Vivimed Labs and its competitors. Vivimed Labs's current Total Long-Term Assets is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.55, compared to a current price of ₹5.36 — trading 110.2% above its estimated fair value. The current Total Long-Term Assets is ₹0.0 Mil. Vivimed Labs' overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Total Long-Term Assets is ₹0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.36 is trading 110.2% above its estimated GF Value™ of ₹2.55. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Total Long-Term Assets: ₹0.0 Mil
  • GF Value™: ₹2.55 vs. price of ₹5.36 (110.2% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
42GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.36
Price
₹2.55
GF Value